L5 pharmacovigilance Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Pharmacovigilance

A

Identification, assessment and prevention of adverse drug reactions while optimising benefits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Who is responsible for pharmacovigilance

A
Prescribers
Patients
Carers 
Health care workers
- to report ADRs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mechanism to manage pharmacovigilance

A

Yellow card reporting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does thalidomide cause

A

Phocomelia- limited or no limb development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How many cases are needed to make a change?

A

10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What was changed due to the thalidomide cases?

A
  • Adequate testing used
  • Government regulations
  • Reporting systems
  • Most medicines cross the placenta
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is thalidomide used for currently?

A

Malignant myeloma in over 65 yr olds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Purposes of early phase trials

A

Identify serious ADRs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Limitations of trials

A
Low frequency of reporting 
Low publishing data 
Confounding variables 
Small number of patients
Not representative 
Short duration
Specialist doctors are needed with short follow up
Concomitant therapeutics usually excluded
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Classes of ADR

A

Type A - Augmented

Type B - Bizarre

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Type A ADR

A
  • Dose related
  • Predictable - PK and PD
  • common
  • reversible
  • Dose adjustment required
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Examples of type A ADR

A

Warfarin causing bleeding

Insulin causing hypoglycaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Type B ADR

A
  • not does related
  • unpredictable
  • uncommon
  • serious or irreversible
  • Stop treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Type B ADR example

A

Penicillin anaphylaxis

Clozapine (used to treat schizophrenia) - agranulocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mechanisms of ADR

A
  • Exaggeration of response
  • Desired pharmacological effect at alternative site/ additional site e.g. GTN spray causes headaches
  • additional secondary pharmacological effect
  • triggers immunological response - anaphylaxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Relative risk

A

Relative risk in a rare condition doesn’t affect no. of cases that much

17
Q

Advantages of reporting

A

Simple mechanism to report
Quick and inexpensive
Detects common and rare reactions
Accessible by all health care professionals and patients

18
Q

Negatives of reporting

A
under reporting 
Positive bias 
Duplication
Effect of publicity and media
Poor quality data
19
Q

Improving reporting

A

Implementing guidance
Medical reviews
Collecting data from under reported areas
Global approach - big data

20
Q

Pharmacogenetics

A

How individual genes may affect response to drugs or side effects

21
Q

Pharmacogenomics

A

Whole genome and epigenetic effect on drug interactions

Population and individual characteristics

22
Q

Individual variability

A

CYP P450 expression
Split antigen reaction
Enzyme deficiency - aldehyde dehydrogenase

23
Q

Abacavir example

A

Abacavir for HIV associated with hypersensitivity with patients that have the split antigen expressed
Therefore screening used - 75% reduction

24
Q

Carbamazepine example

A

Stevens-Johnson syndrome or severe toxic epidermal necrolysis reaction to another split antigen found in Asian people therefore avoid giving to Asian patient group

25
Q

Aldehyde dehydrogenase deficiency

A

Mutated ALDH2
Single point aa mutation
predominant in East Asian population

26
Q

Warfarin

A

Racemix mixture of S and R anomers (S 3-5 x more more potent)
Metabolised by different CYPs
Genetic polymorphism is the expression of particular CYP can change potency of warfarin therefore no standard dose and based of INR

27
Q

CYP 2D6

A

metabolises 25% of drugs but rate highly variable

6% of Caucasians have 2 null alleles therefore no CYP 2D6 activity

28
Q

Use of genetic polymorphism information

A

Personalised drug therapy
Rapid screening of gene variants
Knowledge can be used to target specific receptors or enzymes

e.g. cancer
vaccines for allergies
statin side effect prediction